Crossmark

Treatment with CR500® improves algofunctional scores in patients with knee osteoarthritis: a post-market confirmatory interventional, single arm clinical investigation

Crossref DOI link: https://doi.org/10.1186/s12891-023-06754-7

Published Online: 2023-08-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Colombini, Alessandra

Doro, Gianluca

Ragni, Enrico

Forte, Luca

de Girolamo, Laura

Zerbinati, Fabio
Funding

Funding for this research was provided by:

Contrad Swiss SA
License Information

Text and Data Mining valid from 2023-08-12

Version of Record valid from 2023-08-12
More Information

Article History

Received: 22 December 2022

Accepted: 25 July 2023

First Online: 12 August 2023

Declarations

:

: The study was approved by the independent Ethics Committee of IRCCS Istituto Clinico Humanitas (HMD 913/20, date of approval 15/12/2020). All patients included in this study gave their informed consents.

: Not applicable.

: Dr. Luca Forte is an employee of Contrad Swiss SA. The other authors do not have competing interest.

Document is current

Any future updates will be listed below